Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Tecan to expand U.S. pipette tip manufacturing for COVID-19 testing supported through a $32.9 million investment by the U.S. Government

10/27/2020 | 01:25am EST

Tecan to expand U.S. pipette tip manufacturing for COVID-19 testing supported through a $32.9 million investment by the U.S. Government

  • New U.S. manufacturing lines expected to start pipette tip production in fall 2021
  • Additionally, Tecan has already doubled its worldwide pipette tip production capacity, with further substantial increases in early 2021

Männedorf, Switzerland, October 27, 2020 – The Tecan Group (SIX Swiss Exchange: TECN) announced today that the U.S. Department of Defense (DoD) and the U.S. Department of Health and Human Services (HHS) awarded a USD 32.9 million (CHF 29.8 million) contract to support the buildup of U.S. pipette tip manufacturing for COVID-19 testing. Disposable pipette tips are a key component for molecular tests for SARS-CoV-2 and other assays performed on fully automated, high throughput systems.

Manufacturing equipment used in producing these pipette tips is highly specialized, requiring fully automated production lines capable of precise molding and multiple inline visual quality testing. The funding will support Tecan in launching new production capacity in the U.S. via an expedited process.   This contract award is part of the ongoing collaboration between DoD and HHS, led by the Department’s Joint Acquisition Task Force (JATF) and funded through the CARES Act, to enable and support domestic industrial base expansion for critical medical resources.
The new U.S. manufacturing lines are expected to start producing pipette tips in fall 2021, supporting an increase in domestic testing capacity of several million tests per month by December 2021.
Expanded U.S. production will augment the steps Tecan has already taken to increase global manufacturing capacity at other locations, resulting in a doubling of Tecan’s worldwide pipette tip production capacity, with an additional boost in production expected in early 2021.

“Testing is one of the most important tools in fighting the global COVID-19 pandemic; doing so quickly, effectively and consistently requires both outstanding clinical expertise and high quality technical systems,” said Tecan CEO Dr. Achim von Leoprechting. “We are proud that Tecan’s automation solutions – and the disposable pipette tips they require – are a key part of that process. This investment in expanded U.S. manufacturing capacity supported by the government funding is important for our laboratory and diagnostic testing partners, as well as public health.” 

Tecan is a pioneer and global market leader in laboratory automation. The company’s laboratory automation solutions help laboratories to automate diagnostic testing and make procedures more precise, more efficient and safer. By automating testing, laboratories can significantly increase the volume of samples they process, obtain test results sooner and ensure accurate output. Tecan serves some customers like large clinical reference laboratories directly, but also supplies OEM instruments and pipette tips to diagnostics companies that are used as total solutions together with their relevant test kits.

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2019, Tecan generated sales of CHF 637 million (USD 643 million; EUR 574 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89




Primary Logo

© GlobeNewswire 2020
Latest news "Companies"
05:59pPomerantz Law Firm Announces the Filing of a Class Action against Fortress Biotech, Inc. Certain Officers - FBIO
05:56pGrupo Aeroportuario del Pacifico Announces Conclusion of Extraordinary Review Process of the Master Development Program for the Mexican Airports
05:55pSOURCE ENERGY SERVICES : Obtains Court Approval of its Recapitalization Transaction
05:53pTESLA : U.S. agency opens probe into 115,000 Tesla vehicles over suspension issue
05:51pHyundai, Kia agree to $210 million U.S. auto safety civil penalty
05:51pINFINITY PHARMACEUTICALS : 2020 SITC Oral Presentation
05:49pShell Convent, Louisiana, refinery workers get severance package details - sources
05:48pGT GOLD : Reports Third Quarter 2020 Financial Results
05:42pWaypoint Investment Partners Refiles Interim Management Report of Fund Performance
Latest news "Companies"